Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Tafluprost is a highly potent synthetic prostaglandin F2α analog, primarily utilized in the ophthalmic field for the management of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Its molecular formula is C21H34O5, and it is universally recognized by the CAS number 160778-96-3. As a prodrug, tafluprost possesses a unique chemical structure featuring an isopropyl ester group that renders it lipophilic. Upon instillation into the eye, this ester moiety is rapidly hydrolyzed by endogenous esterases within the cornea to release the active free acid form, tafluprost acid. This activation mechanism significantly enhances ocular penetration while minimizing systemic absorption, thereby improving the therapeutic index and safety profile compared to some older prostaglandin analogs.
The primary clinical utility of tafluprost lies in its ability to lower IOP through two distinct mechanisms: increasing uveoscleral outflow and, to a lesser extent, enhancing trabecular outflow facility. By mimicking the action of natural prostaglandins, it remodels the extracellular matrix of the ciliary body, facilitating fluid drainage from the anterior chamber. Clinical studies have consistently demonstrated that tafluprost provides robust, once-daily dosing efficacy with a rapid onset of action, often achieving maximal IOP reduction within four weeks of treatment initiation. It is frequently prescribed as monotherapy or in combination with other anti-glaucoma agents such as beta-blockers or carbonic anhydrase inhibitors when additional pressure control is required.
Common side effects are generally mild and localized, including transient conjunctival hyperemia, stinging upon application, and potential changes in iris pigmentation or eyelash growth. Unlike some other drugs in its class, tafluprost has shown a favorable safety profile regarding macular edema and cystoid macular edema risk in certain patient populations. Due to its stability and efficacy, tafluprost remains a cornerstone medication in modern glaucoma management protocols worldwide, offering patients a reliable option to preserve visual function and prevent optic nerve damage caused by high intraocular pressure.